Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study)
Abstract
Background: Long-term persistence with antifibrotic drugs is crucial to slow disease progression in fibrosing ILDs but is challenging due to adverse events. Large-scale, real-world studies investigating modifiable healthcare system factors associated with persistence are lacking. Objectives: The main objectives of this study were to assess the real-life persistence with antifibrotic treatments in the overall French population and to explore factors associated with patients' persistence with antifibrotic therapy. Methods: In this retrospective observational study conducted using the French National Health Database System, all adults initiating nintedanib or pirfenidone between January 2019 and December 2021 were included. They were categorized by diagnosis (idiopathic pulmonary fibrosis, interstitial lung disease associated with systemic sclerosis, and progressive pulmonary fibrosis) using International Classification of Diseases 10th Revision codes. Persistence with antifibrotic therapy (defined as no treatment gap longer than 60 days), adherence to antifibrotic treatments, overall survival (OS), and event-free survival (EFS) were assessed. A multivariable Fine-Gray model identified factors associated with non-persistence. Results: Among 4,935 incident patients, the 12-month persistence rate with antifibrotic therapy was 70.8%. The median time of follow-up for incident patients was 27 months. The median time on antifibrotic therapy was 14.1 months. Switching between antifibrotics occurred in 16.6% of patients, mainly during the first year. At 12 months, OS and EFS were 85.8% and 57.4%, respectively, with lower rates observed among patients with IPF. Regular outpatient visits, follow-up in expert centers, and early supportive interventions (day-hospitalization, temporary treatment interruptions) were associated with increased persistence whereas suboptimal follow-up (< 2 pulmonary function tests during the follow-up period) was strongly associated with non-persistence (sHR = 3.1). Conclusion: Structured patient follow-up and proactive management of adverse events, including treatment interruption, could be key to optimizing long-term persistence with antifibrotic therapy.
Related
- Nationwide outbreak of Salmonella Enteritidis linked to consumption of pumpkin seeds, France, 2026
- Uveitis in Patients with Inflammatory Bowel Disease: Pharmacovigilance Signal Detection and Nationwide Claims-Based Evaluation
- Healthcare trajectories diverge years before Huntington disease is recorded in claims: a nationwide French matched cohort study
- Frequencies of thyroid-related diagnoses and dyslipidemia among Japanese women with menstrual-related disorders aged under 40 years: A nationwide cross-sectional study using health insurance claims data
- Access to hospital-based rehabilitation for people with multiple sclerosis in France: A nationwide study (2017–2023)
BibTeX
@article{cottin2026realworld,
title = {{Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study)}},
author = {Vincent Cottin and Marie Najean and Elise Arnee and Malamati Voulgaridou and Clémentine Dillard and Xavier Ansolabehere and Maxime Doublet and Julien Chollet and Sylvie Leroy and Stéphane Jouneau},
journal = {Respiratory Research},
year = {2026},
month = jun,
doi = {10.1186/s12931-026-03754-8},
url = {https://hal.science/hal-05675687v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study)
AU - Vincent Cottin
AU - Marie Najean
AU - Elise Arnee
AU - Malamati Voulgaridou
AU - Clémentine Dillard
AU - Xavier Ansolabehere
AU - Maxime Doublet
AU - Julien Chollet
AU - Sylvie Leroy
AU - Stéphane Jouneau
PY - 2026
DA - 2026/06/19
JO - Respiratory Research
DO - 10.1186/s12931-026-03754-8
UR - https://hal.science/hal-05675687v1
AB - Background: Long-term persistence with antifibrotic drugs is crucial to slow disease progression in fibrosing ILDs but is challenging due to adverse events. Large-scale, real-world studies investigating modifiable healthcare system factors associated with persistence are lacking. Objectives: The main objectives of this study were to assess the real-life persistence with antifibrotic treatments in the overall French population and to explore factors associated with patients' persistence with antifibrotic therapy. Methods: In this retrospective observational study conducted using the French National Health Database System, all adults initiating nintedanib or pirfenidone between January 2019 and December 2021 were included. They were categorized by diagnosis (idiopathic pulmonary fibrosis, interstitial lung disease associated with systemic sclerosis, and progressive pulmonary fibrosis) using International Classification of Diseases 10th Revision codes. Persistence with antifibrotic therapy (defined as no treatment gap longer than 60 days), adherence to antifibrotic treatments, overall survival (OS), and event-free survival (EFS) were assessed. A multivariable Fine-Gray model identified factors associated with non-persistence. Results: Among 4,935 incident patients, the 12-month persistence rate with antifibrotic therapy was 70.8%. The median time of follow-up for incident patients was 27 months. The median time on antifibrotic therapy was 14.1 months. Switching between antifibrotics occurred in 16.6% of patients, mainly during the first year. At 12 months, OS and EFS were 85.8% and 57.4%, respectively, with lower rates observed among patients with IPF. Regular outpatient visits, follow-up in expert centers, and early supportive interventions (day-hospitalization, temporary treatment interruptions) were associated with increased persistence whereas suboptimal follow-up (< 2 pulmonary function tests during the follow-up period) was strongly associated with non-persistence (sHR = 3.1). Conclusion: Structured patient follow-up and proactive management of adverse events, including treatment interruption, could be key to optimizing long-term persistence with antifibrotic therapy.
SN - 1465-9921
ER -